Department of Pathology, Hacettepe University School of Medicine, Ankara, Turkey.
Clinic of Pathology, Erzurum Regional Training and Research Hospital, Erzurum, Turkey.
Balkan Med J. 2017 Dec 1;34(6):567-571. doi: 10.4274/balkanmedj.2017.0297. Epub 2017 Aug 23.
mutation analysis in non-small cell lung cancer is important for selecting patients who will receive treatment with tyrosine kinase inhibitors. In this study, we aimed to investigate the prevalence of epidermal growth factor receptor mutations and mutation patterns in the Turkish population.
We retrospectively reviewed molecular pathology reports of 959 cases with lung cancer analysed for receptor mutations. We analysed all four receptor exon mutations using a real-time polymerase chain reaction platform.
In this study, the mutation rate in the Turkish population was 16.7% (160 of 959). The mutation frequency was significantly higher in women (37.1%, n=96) than in men (9.1%, n=64) (p<0.001). In addition, the mutation rate was higher in the adenocarcinoma histologic type (p<0.001). Patients with mutations were older than those without mutations (p=0.003). The most frequent mutations were exon 19 deletions (48.8%, 78/160) and exon 21 L858R point mutations (38.1.1%, 61/160). We also detected compound mutation patterns in three cases (1.9%).
The prevalence of receptor mutations in the Turkish population was slightly higher than that in the Caucasian population and lower than that in the East Asian population. The results of this study may provide guidance in personalized therapy of non-small cell lung cancer in the Turkish population.
非小细胞肺癌中的突变分析对于选择接受酪氨酸激酶抑制剂治疗的患者非常重要。在这项研究中,我们旨在调查土耳其人群中表皮生长因子受体突变的流行率和突变模式。
我们回顾性地分析了 959 例肺癌患者的分子病理学报告,这些患者均接受了 受体突变分析。我们使用实时聚合酶链反应平台分析了所有四个 受体外显子突变。
在这项研究中,土耳其人群中的 突变率为 16.7%(959 例中有 160 例)。女性(37.1%,n=96)的 突变频率明显高于男性(9.1%,n=64)(p<0.001)。此外,腺癌组织学类型的 突变率更高(p<0.001)。有突变的患者比没有突变的患者年龄更大(p=0.003)。最常见的突变是外显子 19 缺失(48.8%,78/160)和外显子 21 L858R 点突变(38.1.1%,61/160)。我们还在三例患者中检测到了复合突变模式(1.9%)。
土耳其人群中 受体突变的流行率略高于白种人群,低于东亚人群。本研究的结果可为土耳其人群中非小细胞肺癌的个体化治疗提供指导。